Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0002053359-25-000002
Filing Date
2025-01-31
Accepted
2025-01-31 12:44:27
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7887
  Complete submission text file 0002053359-25-000002.txt   9519
Mailing Address 8975 S. PECOS ROAD, UNIT #6A HENDERSON NV 89074
Business Address
Walters William T (Filed by) CIK: 0001689655 (see all company filings)

Type: SCHEDULE 13G/A

Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Subject) CIK: 0001725160 (see all company filings)

EIN.: 823607803 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91478 | Film No.: 25577181
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)